[go: up one dir, main page]

ES2071227T3 - Composicion para gotas para los ojos. - Google Patents

Composicion para gotas para los ojos.

Info

Publication number
ES2071227T3
ES2071227T3 ES91307275T ES91307275T ES2071227T3 ES 2071227 T3 ES2071227 T3 ES 2071227T3 ES 91307275 T ES91307275 T ES 91307275T ES 91307275 T ES91307275 T ES 91307275T ES 2071227 T3 ES2071227 T3 ES 2071227T3
Authority
ES
Spain
Prior art keywords
composition
eye drops
benzoxadine
tioxo
dihidro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91307275T
Other languages
English (en)
Inventor
Kazumichi Ushio
Yoshifumi Ikejiri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2071227T3 publication Critical patent/ES2071227T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE DESCRIBE UNA COMPOSICION DE GOTAS PARA LOS OJOS QUE CONTIENEN COMO COMPONENTE PRINCIPAL EFECTIVO UN ACIDO 3, 4-DIHIDRO-2, 8-DIISOPROPIL3-TIOXO-2H-1, 4-BENZOXADINA-4-ACETICO O UNA SAL SUYA FARMACEUTICAMENTE ACEPTABLE Y CICLODEXTRINA.
ES91307275T 1990-08-13 1991-08-08 Composicion para gotas para los ojos. Expired - Lifetime ES2071227T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21482790 1990-08-13
JP16285491 1991-07-03

Publications (1)

Publication Number Publication Date
ES2071227T3 true ES2071227T3 (es) 1995-06-16

Family

ID=26488494

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91307275T Expired - Lifetime ES2071227T3 (es) 1990-08-13 1991-08-08 Composicion para gotas para los ojos.

Country Status (16)

Country Link
US (1) US5663170A (es)
EP (1) EP0472327B1 (es)
JP (1) JP2769253B2 (es)
KR (1) KR920003971A (es)
AT (1) ATE121295T1 (es)
AU (1) AU633754B2 (es)
CA (1) CA2048942A1 (es)
DE (1) DE69109021T2 (es)
DK (1) DK0472327T3 (es)
ES (1) ES2071227T3 (es)
FI (1) FI97777C (es)
HU (1) HU207950B (es)
NO (1) NO177845C (es)
PT (1) PT98643B (es)
RU (1) RU2068260C1 (es)
TW (1) TW200402B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ260093A3 (en) * 1992-03-18 1994-07-13 Coopervision Pharma VERAPAMIL HCl PREPARATION AND OTHER OPHTHALMIC SOLUTIONS WITH A BUFFER SYSTEM FOR EYE ADMINISTRATION
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
WO1994010976A1 (en) * 1992-11-16 1994-05-26 Ciba Vision Ag, Hettlingen Polyvinyl alcohol/borate ophthalmic drug delivery system
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
SE501482C2 (sv) * 1993-06-24 1995-02-27 Leiras Oy Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning
EP0711147A1 (en) * 1993-07-28 1996-05-15 Insite Vision Incorporated Suspensions for delivery of medicament
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
WO1996001558A1 (en) * 1994-07-11 1996-01-25 Pate David W Anandamide analogue compositions and method of treating intraocular hypertention using same
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
HUT77445A (hu) * 1995-01-20 1998-04-28 Wakamoto Pharmaceutical Co. Ltd. Gyulladásgátló szemcsepp
DE69526369T2 (de) * 1995-01-20 2002-11-07 Wakamoto Pharmaceutical Co., Ltd. Entzündungshemmende augentropfen
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2000012137A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
JP2001125052A (ja) * 1999-10-25 2001-05-11 Lion Corp コンタクトレンズ装着液
CA2413088C (en) * 2000-06-19 2009-10-20 Kenji Morishima Preservative
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
JPWO2006137433A1 (ja) * 2005-06-21 2009-01-22 わかもと製薬株式会社 レボカバスチンを可溶化させた水性薬剤
US20100069335A1 (en) * 2005-07-15 2010-03-18 Rajiv Bhushan Prevention and Treatment of Ophthalmic Complications of Diabetes
CA2868390C (en) 2012-03-26 2020-03-31 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol
TW202014194A (zh) * 2018-04-27 2020-04-16 美商歐樂根公司 抗微生物功效增強且毒性降低之亞氯酸鈉組成物
WO2021101344A1 (ko) * 2019-11-21 2021-05-27 삼진제약주식회사 안질환 예방 또는 치료용 점안 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU602641B2 (en) * 1986-04-17 1990-10-18 Senju Pharmaceutical Co., Ltd. Thiolactam-N-acetic acid derivatives, their production and use

Also Published As

Publication number Publication date
NO913136L (no) 1992-02-14
US5663170A (en) 1997-09-02
TW200402B (es) 1993-02-21
KR920003971A (ko) 1992-03-27
NO913136D0 (no) 1991-08-12
NO177845C (no) 1995-12-06
FI913811A0 (fi) 1991-08-12
HUT61196A (en) 1992-12-28
ATE121295T1 (de) 1995-05-15
AU633754B2 (en) 1993-02-04
DE69109021D1 (de) 1995-05-24
FI97777B (fi) 1996-11-15
PT98643A (pt) 1992-07-31
NO177845B (no) 1995-08-28
DE69109021T2 (de) 1995-09-21
HU207950B (en) 1993-07-28
EP0472327B1 (en) 1995-04-19
EP0472327A1 (en) 1992-02-26
FI97777C (fi) 1997-02-25
CA2048942A1 (en) 1992-02-14
JP2769253B2 (ja) 1998-06-25
RU2068260C1 (ru) 1996-10-27
PT98643B (pt) 1999-01-29
JPH05213757A (ja) 1993-08-24
AU8170891A (en) 1992-02-20
HU912692D0 (en) 1992-01-28
DK0472327T3 (da) 1995-05-08
FI913811L (fi) 1992-02-14

Similar Documents

Publication Publication Date Title
ES2071227T3 (es) Composicion para gotas para los ojos.
ATE167476T1 (de) Substituierte 2-phenyl-3-methocypropensäurenester als fungizide mittel.
AU545023B2 (en) Optically active 1,4-dihydropyridine compound
ES2056071T3 (es) Triazolinonas substituidas.
BR8701885A (pt) Processo para preparar um concentrado claro,estavel ao armazenamento,produto assim preparado,processo para preparar um desinfetante e desinfetante produzido pelo mesmo
ATE181656T1 (de) Intraoculares linsensystem
CY1350A (en) Improvements in or relating to 3-aryloxy-3-phenylpropylamines
ES2051700T3 (es) Un proceso para la preparacion de un compuesto beta-lactama.
SE8404019L (sv) Oftalmiska antiinflammatoriska medel
FI931250A0 (fi) Sulfonamido- och sulfonamidokarbonyl-pyridin-2-karboxylsyraamider och deras pyridin-n-oxider, foerfarande foer deras framstaellning och deras anvaendning som laekemedel
SE8305864D0 (sv) Ogondroppar
BR9102016A (pt) Colheitadeira integral para cana-de-acucar
FI893823L (fi) Foerfarande och anordning foer att limma (hopknippa) stansade elskivor.
ES2083315B1 (es) Procedimiento para preparar compuestos de isoquinolina como agentes bloqueadores neuromusculares.
ES516198A0 (es) "un procedimiento para la preparacion de derivados tetrassubstitudos del benceno".
AR227031A1 (es) Esteres alquilicos del acido n'-(fenilsulfonil)-n-((1,-3,5-triazin o pirimidin)-2-il)carbamimidico y una composicion para el control de la vegetacion no deseada que los contiene
ES2187534T3 (es) Procedimiento para la preparacion de n-metil-3-(metil-4-piperi dinil)-14-indol-5-etanosulfonamida.
ES2105074T3 (es) Compuestos basados en 3,4-diaril-(5h)-furan-2-ona, con actividad fungicida.
ES2103575T3 (es) Procedimiento para la preparacion de 9-(2-hidroxi)-etoximetil-guanina.
AP8800109A0 (en) "Heterocyclic insecticides".
BR8906227A (pt) Processo para preparar benzeno 3,4-difluoro substituido
DE69116224D1 (de) Behandlung von intraokularem Druck mit einer synergischen Kombination
KR920002828A (ko) 높은 동위체 순도의 단결정 다이아몬드로부터 제조된 방사선에 견고한 광학 제품
YU46914B (sh) Metoksimetilna jedinjenja
ES2163501T3 (es) Agente para la disminucion de la tension ocular.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 472327

Country of ref document: ES